RESEARCH-USE BIOSIMILAR ANTIBODY
Garivulimab
Monoclonal antibody · IgG1
Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonal antibody that specifically targets and binds to PD-L1. Garivulimab selectively blocks the interaction of PD-L1 and PD-1. Garivulimab has antitumor activity.
TARGETPDL1
YMonoclonal antibody
CATALOGSC-BS-514
CATALOG NUMBERSC-BS-514
MOLECULAR WEIGHTApprox. 143.9 kDa
PRODUCT FORMATMonoclonal antibody
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonal antibody that specifically targets and binds to PD-L1. Garivulimab selectively blocks the interaction of PD-L1 and PD-1. Garivulimab has antitumor activity.
Garivulimab is a recombinant research-use antibody directed against PDL1.